TGA reports torn oesophagus after unapproved retatrutide contained semaglutide

The wire

1. 01Australia's Therapeutic Goods Administration said a patient was hospitalised with a torn oesophagus after uncontrollable vomiting; testing of the product sold as retatrutide found semaglutide at about eight times the concentration of approved products.
2. 02Gastroenterologist Darcy Holt said an untreated oesophageal rupture can be life-threatening and that he now asks about peptide use routinely, having seen a marked rise in patients reporting unapproved retatrutide.
3. 03The TGA reiterated retatrutide is still in human clinical trials and unapproved, and warned of unknown contents and non-sterility; liver toxicity and severe secretory diarrhoea have also been reported.

From the source

Patient suffers torn oesophagus after using unapproved weight-loss peptide retatrutide

A patient has faced severe health consequences after using an unapproved peptide marketed as the weight-loss drug retatrutide, leading to hospitalisation for a torn oesophagus. The Therapeutic Goods Administration (TGA) disclosed this alarming case to the media as part of its ongoing warnings about the dangers of unapproved peptides.